Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Thorpy

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Annals of Neurology|January 30, 2019
A randomized study of solriamfetol for excessive sleepiness in narcolepsyMichael J Thorpy, Colin Shapiro, Geert Mayer, et al.
CNS Drugs|May 31, 2022
Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic MedicationsYves Dauvilliers, Karel Šonka, Richard K Bogan, et al.
CNS Drugs|June 28, 2022
Correction to: Changes in Cataplexy Frequency in a Clinical Trial of Lower‑Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic MedicationsYves Dauvilliers, Karel Šonka, Richard K Bogan, et al.
Journal of the American Geriatrics Society|June 2, 2009
Evidence-based recommendations for the assessment and management of sleep disorders in older personsHarrison G Bloom, Imran Ahmed, Cathy A Alessi, et al.
Nature and Science of Sleep|November 2, 2022
Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic HypersomniaMichael J Thorpy, Isabelle Arnulf, Nancy Foldvary-Schaefer, et al.
Clinical Drug Investigation|February 10, 2026
Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic PotentialEric Konofal, Isabelle Arnulf, Jean-Charles Bizot, et al.
The Lancet. Neurology|December 23, 2021
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal studyYves Dauvilliers, Isabelle Arnulf, Nancy Foldvary-Schaefer, et al.
Sleep Medicine|January 12, 2020
Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsyHelene A Emsellem, Michael J Thorpy, Gert Jan Lammers, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Annals of Neurology|January 30, 2019
A randomized study of solriamfetol for excessive sleepiness in narcolepsyMichael J Thorpy, Colin Shapiro, Geert Mayer, et al.
CNS Drugs|May 31, 2022
Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic MedicationsYves Dauvilliers, Karel Šonka, Richard K Bogan, et al.
CNS Drugs|June 28, 2022
Correction to: Changes in Cataplexy Frequency in a Clinical Trial of Lower‑Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic MedicationsYves Dauvilliers, Karel Šonka, Richard K Bogan, et al.
Journal of the American Geriatrics Society|June 2, 2009
Evidence-based recommendations for the assessment and management of sleep disorders in older personsHarrison G Bloom, Imran Ahmed, Cathy A Alessi, et al.
Nature and Science of Sleep|November 2, 2022
Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic HypersomniaMichael J Thorpy, Isabelle Arnulf, Nancy Foldvary-Schaefer, et al.
Clinical Drug Investigation|February 10, 2026
Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic PotentialEric Konofal, Isabelle Arnulf, Jean-Charles Bizot, et al.
The Lancet. Neurology|December 23, 2021
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal studyYves Dauvilliers, Isabelle Arnulf, Nancy Foldvary-Schaefer, et al.
Sleep Medicine|January 12, 2020
Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsyHelene A Emsellem, Michael J Thorpy, Gert Jan Lammers, et al.
Pageof 8